JAMDA
Volume 9, Issue 3 , Pages 199-200 , March 2008

Warfarin Monitoring Woes: A Glimmer of Hope with Pharmacogenomics

  • Manju T. Beier, Pharm D, FASCP

      Affiliations

    • Corresponding Author InformationAddress correspondence to Manju T. Beier, Pharm D, FASCP, University of Michigan, 2001 Commonwealth, Suite 205, Ann Arbor, MI 48105.

References 

  1. McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001;161:2458–2463
  2. Gurwitz JH, Field TS, Radford MJ, et al. The safety of warfarin therapy in the nursing home setting. Am J Med. 2007;120:539–544
  3. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147:755–765
  4. Beier MT. Warfarin monitoring: consider the three Ds. J Am Med Dir Assoc. 2005;6:76
  5. Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy. 2007;27:1237–1247
  6. Food and Drug Administration. New Labeling Information for Warfarin. 2007;Available at: http://www.fda.gov/cder/drug/infopage/warfarin/default.htm. Accessed December 7
  7. Food and Drug Administration. FDA Clears Genetic Lab Test for Warfarin Sensitivity. 2007;Available at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01701.html. Accessed December 7
  8. Food and Drug Administration. FDA’s Critical Path Initiative: Warfarin Dosing. 2007;Available at: http://www.fda.gov/oc/initiatives/criticalpath/warfarin.html. Accessed December 7

 The author has no conflict of interest regarding this article.

PII: S1525-8610(07)00529-4

doi: 10.1016/j.jamda.2007.12.007

JAMDA
Volume 9, Issue 3 , Pages 199-200 , March 2008

Article Tools